

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE

The board (the “**Board**”) of directors (the “**Directors**”) of the GenScript Biotech Corporation (the “**Company**”) is pleased to announce that on 22 September 2021, Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, announced that it will host its first Research & Development Day on Monday, 18 October, 2021, commencing at 10:00 a.m. (New York time), at the Andaz 5th Avenue in New York, the United States.

The pipeline meeting will feature updates on Legend Biotech’s advancing of hematological and oncological indications and expanding cell therapy capabilities, including its B cell maturation antigen (BCMA) clinical development program. Presentations will be delivered by Legend Biotech’s senior leadership team:

- Ying Huang, PhD, Chief Executive Officer and Chief Financial Officer
- Frank Fan, MD, PhD, Chief Scientific Officer
- Steve Gavel, Vice President, US & Europe Commercial
- Lida Pacaud, MD, Vice President, Clinical Development

A live webcast and presentation will be available to investors and other interested parties on the Legend Biotech’s website under “Events and Presentations” at <https://investors.legendbiotech.com/events-and-presentations>. A recording of the webcast can be viewed as early as 24 hours after the event and will be archived for six months.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 23 September 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*